Determining the maximum tolerable dose and pharmacokinetic parameters of intravenous PTHrP(1-36) [parathyroid hormone-1-36]
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Parathyroid hormone 1-36 (Primary)
- Indications Osteoporosis
- Focus Adverse reactions
- 05 Sep 2014 Biomarkers information updated
- 23 Jan 2009 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
- 14 Feb 2008 The expected completion date for this trial is now .